West Cancer Center

Revolution Slider Error: Trying to get property of non-object

Head And Neck: Phase 1: NKG2A inhibitor: CA047004

A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or
Cetuximab in Participants with Advanced Solid Tumors

Title

Bristol-Myers Squibb CA047004 (Phase 1 NKG2A inhibitor- Head and Neck)

Study Title

A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination with Nivolumab or
Cetuximab in Participants with Advanced Solid Tumors

Site Link

NCT04349267

Malignancy

Head and neck cancer (SCCHN), laryngeal, hypopharyngeal, oropharyngeal, oral cavity, oropharynx, hypopharynx, larynx

Stage

Stage 4

Disease Setting

ADVANCED/METASTATIC

Line Of Therapy

> or = 2nd line

Investigational Agent

BMS-986315 with either nivolumab or cetuximab

Drug Class

NKG2A inhibitor

Dan Vaena, MD

Sponsor

Bristol-Myers Squibb

Phase

Phase 1

Status

Open to Enrollment

Key Eligibility Criteria

Key Eligibility Criteria Details

Objective

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

squamous cell carcinoma

Dosing Frequency

Control Agents

Study Protocol

Randomized